ストックスクリーナーアプリを入手
9.888
0.32%
-0.032
前日終値:
$9.92
開ける：
$9.945
24時間の取引高:
1,198
Relative Volume:
0.28
時価総額：
$83.74M
収益：
$70,100
当期純損益:
$-9.16M
株価収益率:
-9.0491
EPS:
-1.0927
ネットキャッシュフロー:
$-6.67M
1週間 パフォーマンス:
-4.23%
1か月 パフォーマンス:
+13.14%
6か月 パフォーマンス:
-26.76%
1年 パフォーマンス:
-8.87%
1日の値動き範囲:
$9.80
$9.945
1週間の範囲:
$9.66
$10.50
52週間の値動き範囲:
$7.08
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Compare EXOZ vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
9.888 | 84.01M | 70,100 | -9.16M | -6.67M | -1.0927 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exozymes Inc (EXOZ) 最新ニュース
Video Interview: Successful Pilot-Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability - The National Law Review
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Dr - The National Law Review
eXoZymes (NASDAQ:EXOZ) Shares Down 0.4%Should You Sell? - MarketBeat
Damien Alan Perriman Net Worth (2026) - GuruFocus
EXOZ Technical Analysis | Trend, Signals & Chart Patterns | EXOZYMES INC (NASDAQ:EXOZ) - ChartMill
eXoZymes Advances Toward Planned Securities Offering Preparation - The Globe and Mail
Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (E - GuruFocus
eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast By Investing.com - Investing.com Australia
Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast - Investing.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire
Why eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan
Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Exozymes Incannounces common stock offeringSEC filing - marketscreener.com
eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan
Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
EXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan
Insider Trends: Can eXoZymes Inc sustain earnings growthMarket Sentiment Review & Growth Oriented Trading Recommendations - baoquankhu1.vn
Latest EXOZ ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
EXOZ Technical Analysis & ETF Price Forecast - Intellectia AI
EXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant - Stock Titan
EXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant - Stock Titan
[Form 4] EXOZYMES INC. Insider Trading Activity - Stock Titan
Exozymes (EXOZ) CSO receives 5,332-share stock award - Stock Titan
Bond Watch: Is eXoZymes Inc a speculative investment2026 Price Swings & Detailed Earnings Play Strategies - baoquankhu1.vn
Does eXoZymes Inc stock have upside surprise potential2026 Fundamental Recap & Weekly Market Pulse Updates - baoquankhu1.vn
EXOZ PE Ratio & Valuation, Is EXOZ Overvalued - Intellectia AI
Nasdaq Moves: Is eXoZymes Inc forming a bullish divergenceShare Buyback & High Accuracy Buy Signal Tips - baoquankhu1.vn
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Bitget
EXOZ: NCT achieved kilo-scale production and tech transfer, with a financing round in progress - TradingView — Track All Markets
eXoZymes Inc's Capital Raise Delays and NCT Timeline Shifts Highlight Strategic Contradictions - Bitget
eXoZymes Q4 Earnings Call Highlights - MarketBeat
EXOZ: Pilot-scale NCT production achieved; financing round underway to support 2027 commercial launch - TradingView
Earnings call transcript: eXoZymes Q4 2025 results show strategic focus - Investing.com
eXoZymes ends 2025 with $3.04M cash as financing round nears - Stock Titan
eXoZymes Updates Investor Presentation for NCTx Business - TipRanks
eXoZymes (NASDAQ: EXOZ) files updated NCTx investor presentation - Stock Titan
eXoZymes Q4 2025 Earnings Call Transcript - MarketBeat
eXoZymes (NASDAQ: EXOZ) outlines exozyme platform and NCT plans - Stock Titan
EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Institution Moves: Can eXoZymes Inc sustain earnings growth2026 Geopolitical Influence & Technical Pattern Recognition Alerts - baoquankhu1.vn
Why Use Living Cells? NLR Is Making Chemicals With Enzymes Alone - nlr.gov
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - ACCESS Newswire
EXOZ Price Today: eXoZymes Inc. Stock Price, Quote & Chart - MEXC Exchange
Whale Trades: Can eXoZymes Inc sustain earnings growthRate Hike & High Accuracy Investment Entry Signals - baoquankhu1.vn
eXoZymes (NASDAQ:EXOZ) Shares Up 2.4%What's Next? - MarketBeat
Momentum Shift: Is eXoZymes Inc forming a bullish divergenceForecast Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
Exozymes Inc (EXOZ) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):